OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
35
Results
Show all
Save search
Copy query
Show results for
Unknown
(35)
Publication Date
Release Date
2022
(9)
2021
(9)
2023
(6)
2020
(4)
2024
(2)
2019
(2)
2025
(1)
2015
(1)
2011
(1)
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Not available
S-EPMC7042998
|
biostudies-literature
Cite
Gene-ontology enrichment analysis in two independent family-based samples highlights biologically plausible processes for autism spectrum disorders.
Not available
S-EPMC3190264
|
biostudies-literature
Cite
Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery.
Not available
S-EPMC10163929
|
biostudies-literature
Cite
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.
Not available
S-EPMC8189635
|
biostudies-literature
Cite
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Not available
S-EPMC11117088
|
biostudies-literature
Cite
Whole-genome sequence-based analysis of thyroid function.
Not available
S-EPMC4366514
|
biostudies-literature
Cite
Postoperative critical care and high-acuity care provision in the United Kingdom, Australia, and New Zealand.
Not available
S-EPMC6435907
|
biostudies-literature
Cite
Federated learning enables big data for rare cancer boundary detection.
Not available
S-EPMC9722782
|
biostudies-literature
Cite
Four consecutive yearly point-prevalence studies in Wales indicate lack of improvement in sepsis care on the wards.
Not available
S-EPMC8355110
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets